Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?

Sarcomas are a group of diverse and complex cancers of mesenchymal origin that remains poorly understood. Recent developments in cancer immunotherapy have demonstrated a potential for better outcomes with immune checkpoint inhibition in some sarcomas compared to conventional chemotherapy. Immune che...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiong, Chin Sern, Lin, Tzu Ping, Lim, Vivian Yujing, Toh, Tan Boon, Yang, Valerie Shiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463641/
https://www.ncbi.nlm.nih.gov/pubmed/37612756
http://dx.doi.org/10.1186/s40364-023-00513-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463641/
https://www.ncbi.nlm.nih.gov/pubmed/37612756
http://dx.doi.org/10.1186/s40364-023-00513-5

Ejemplares similares